Loading...
XNYSNNVC
Market cap15mUSD
Jan 10, Last price  
1.35USD
1D
-2.88%
1Q
-9.40%
Jan 2017
-93.69%
Name

NanoViricides Inc

Chart & Performance

D1W1MN
XNYS:NNVC chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
27.02%
Rev. gr., 5y
%
Revenues
0k
Net income
-8m
L-3.43%
-66,005-3,284,432-3,118,963-2,738,337-2,787,798-4,744,208-6,477,165-6,207,207-8,875,668-14,106,474-2,198,172-10,724,629-10,304,490-8,563,455-8,244,695-13,397,539-8,907,594-8,100,127-8,588,573-8,294,146
CFO
-6m
L+11.38%
0-1,823,575-2,333,132-2,550,258-2,682,040-2,047,522-4,507,668-4,217,986-5,797,772-6,333,625-6,212,332-6,829,195-7,897,746-7,775,868-6,802,770-6,665,603-8,213,837-5,891,254-5,670,051-6,315,507
Earnings
Feb 12, 2025

Profile

NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
URL
http://www.nanoviricides.com/
IPO date
Aug 12, 2004
Employees
17
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
Cost of revenue
9,275
9,691
8,837
Unusual Expense (Income)
NOPBT
(9,275)
(9,691)
(8,837)
NOPBT Margin
Operating Taxes
356
(7)
Tax Rate
NOPAT
(9,275)
(10,047)
(8,830)
Net income
(8,294)
-3.43%
(8,589)
6.03%
(8,100)
-9.06%
Dividends
Dividend yield
Proceeds from repurchase of equity
3,120
BB yield
-15.28%
Debt
Debt current
95
Long-term debt
Deferred revenue
Other long-term liabilities
1,500
153
Net debt
(4,798)
(8,150)
(13,972)
Cash flow
Cash from operating activities
(6,316)
(5,670)
(5,891)
CAPEX
(157)
(152)
(324)
Cash from investing activities
(157)
(152)
(324)
Cash from financing activities
3,120
(95)
(235)
FCF
(8,681)
(9,427)
307,093,273
Balance
Cash
4,798
8,150
14,066
Long term investments
Excess cash
4,798
8,150
14,066
Stockholders' equity
(139,375)
(131,081)
(122,480)
Invested Capital
150,839
147,446
145,657
ROIC
ROCE
EV
Common stock shares outstanding
11,871
11,626
11,535
Price
1.72
49.57%
1.15
-38.83%
1.88
-59.48%
Market cap
20,418
52.71%
13,370
-38.34%
21,685
-57.13%
EV
15,620
5,220
7,714
EBITDA
(8,516)
(8,943)
(8,114)
EV/EBITDA
Interest
938
5
Interest/NOPBT